CN115381005B - 植物乳杆菌cicc 6240在消减水产品体内抗生素残留中的应用 - Google Patents
植物乳杆菌cicc 6240在消减水产品体内抗生素残留中的应用 Download PDFInfo
- Publication number
- CN115381005B CN115381005B CN202211026125.2A CN202211026125A CN115381005B CN 115381005 B CN115381005 B CN 115381005B CN 202211026125 A CN202211026125 A CN 202211026125A CN 115381005 B CN115381005 B CN 115381005B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- cicc
- application
- enrofloxacin
- chloramphenicol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 62
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 62
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 62
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 50
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims abstract description 62
- 229960000740 enrofloxacin Drugs 0.000 claims abstract description 62
- 229960005091 chloramphenicol Drugs 0.000 claims abstract description 61
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims abstract description 61
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 238000009629 microbiological culture Methods 0.000 claims abstract description 10
- 230000006907 apoptotic process Effects 0.000 claims abstract description 9
- 230000036039 immunity Effects 0.000 claims abstract description 7
- 230000003647 oxidation Effects 0.000 claims abstract description 7
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 7
- 241000252233 Cyprinus carpio Species 0.000 claims description 44
- 239000003242 anti bacterial agent Substances 0.000 claims description 22
- 229940088710 antibiotic agent Drugs 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 230000037257 muscle growth Effects 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 244000164595 Lactobacillus plantarum subsp plantarum Species 0.000 claims 5
- 235000012523 Lactobacillus plantarum subsp plantarum Nutrition 0.000 claims 5
- 230000028709 inflammatory response Effects 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 abstract description 44
- 230000000694 effects Effects 0.000 abstract description 22
- 210000003205 muscle Anatomy 0.000 abstract description 13
- 241001465754 Metazoa Species 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 5
- 238000009360 aquaculture Methods 0.000 abstract description 4
- 244000144974 aquaculture Species 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 4
- 241000611735 Paenibacillus peoriae Species 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 44
- 238000012360 testing method Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 18
- 230000035882 stress Effects 0.000 description 15
- 238000005259 measurement Methods 0.000 description 14
- 238000010586 diagram Methods 0.000 description 13
- 239000003640 drug residue Substances 0.000 description 12
- 108010056785 Myogenin Proteins 0.000 description 10
- 102000004364 Myogenin Human genes 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 102000016943 Muramidase Human genes 0.000 description 7
- 108010014251 Muramidase Proteins 0.000 description 7
- 108010056852 Myostatin Proteins 0.000 description 7
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 229960000274 lysozyme Drugs 0.000 description 7
- 239000004325 lysozyme Substances 0.000 description 7
- 235000010335 lysozyme Nutrition 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 102000004472 Myostatin Human genes 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 5
- 102000013563 Acid Phosphatase Human genes 0.000 description 5
- 108010051457 Acid Phosphatase Proteins 0.000 description 5
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- 108010063907 Glutathione Reductase Proteins 0.000 description 5
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
- OTRFVHWXENKCEG-ONEGZZNKSA-N Carpacin Chemical compound C1=C(\C=C\C)C(OC)=CC2=C1OCO2 OTRFVHWXENKCEG-ONEGZZNKSA-N 0.000 description 3
- 108010028780 Complement C3 Proteins 0.000 description 3
- 102000016918 Complement C3 Human genes 0.000 description 3
- 108010028778 Complement C4 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 101150013833 MYOD1 gene Proteins 0.000 description 3
- 101100239689 Takifugu rubripes myod gene Proteins 0.000 description 3
- 101100239691 Xenopus laevis myod1-a gene Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000252210 Cyprinidae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 101710180313 Protease 3 Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- -1 etc.) Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 101710173948 Cysteine proteinase 3 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710089042 Demethyl-4-deoxygadusol synthase Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101100441247 Lactiplantibacillus plantarum (strain ATCC BAA-793 / NCIMB 8826 / WCFS1) csp gene Proteins 0.000 description 1
- 101100441253 Lactiplantibacillus plantarum (strain ATCC BAA-793 / NCIMB 8826 / WCFS1) cspL gene Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 101000613148 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Calpain-like protease palB/cpr-8 Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 101150068339 cspLA gene Proteins 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 101150042523 myod gene Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- NEGYEDYHPHMHGK-UHFFFAOYSA-N para-methoxyamphetamine Chemical compound COC1=CC=C(CC(C)N)C=C1 NEGYEDYHPHMHGK-UHFFFAOYSA-N 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000004562 water dispersible granule Substances 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/26—Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
- A23K10/37—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from waste material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/28—Silicates, e.g. perlites, zeolites or bentonites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Pain & Pain Management (AREA)
Abstract
本发明涉及水产养殖领域,具体涉及植物乳杆菌在消减水产品体内抗生素残留中的应用或在制备消减水产品体内抗生素残留的产品中的应用。所述植物乳杆菌(Paenibacillus peoriae)的菌株号为CICC 6240,其在中国工业微生物菌种保藏管理中心的登记入册编号为CICC 6240。实验证明,本发明的植物乳杆菌CICC 6240具有加速鱼体氯霉素与恩诺沙星在鱼体消减;提高鱼体抗氧化能力、改善鱼体非特异性免疫、抑制炎症反应以及抑制组织细胞凋亡;并且提高鱼体肌肉品质的作用。此外,植物乳杆菌CICC 6240作为商品菌,广泛适用于水生动物,有望成为水生动物减抗退抗的新途径,从而推广应用与开发。
Description
技术领域
本发明涉及水产养殖领域,具体涉及植物乳杆菌在消减水产品中抗生素残留中的应用。
背景技术
近年来,水产品的抗生素残留问题受到世界各国的高度重视。在实际高密集养殖中,抗生素作为高效抗菌和疾病防治的特效药物,被频繁使用,造成了严重的抗生素污染。研究表明只有一少部分的抗生素可被水产动物吸收利用,大量的抗生素未被完全代谢,残留在养殖环境以及水产动物体内。这不仅会改变环境中的微生物区系、破坏水域微生态平衡、对细菌产生选择压力诱导抗生素抗性基因和超级耐药菌株;而且还会导致养殖产品中残留抗生素通过食物链传播,危害水产品质量安全,最终对人类健康造成潜在威胁。加速消减水产动物体内抗生素残留是一种提高水产养殖产品安全的重要策略。
研究表明,益生菌具有消减Pb、Cr、Hg等重金属在动物体内残留的功效。如:Lactobacillus plantarum CCFM8661通过增加胆汁酸的产生,螯合肠道内Pb,将Pb转化为草酸铅,加速排出体内;铬酸盐抗性的乳酸杆菌拥有在机体胃肠道及被污染的环境中结合铬(VI)的潜力,且在小鼠试验中,肠道菌群可以将高毒性的铬(VI)转化为毒性较低的铬(III);同时,某些细胞表面存在许多汞结合蛋白,为益生菌细胞结合汞提供了可能。除了具有表面结合甲基汞的能力之外,少数乳酸菌自身可能还存在编码甲基汞裂解酶的基因,因此自身的酶促反应可能是其结合甲基汞的机制之一。此外,有报道表明益生菌对抗生素诱导的氧化应激、炎症反应也有一定的缓解作用,其原因一方面可能是益生菌具有增强机体免疫力、抗氧化能力,另一方面则可能是由于益生菌直接对抗生素残留进行消减。
发明内容
本发明所要解决的技术问题是如何对水产品的抗生素残留进行消减。
本发明提供了植物乳杆菌在消减水产品体内抗生素残留中的应用或在制备消减水产品体内抗生素残留的产品中的应用。
上述应用中,所述植物乳杆菌为植物乳杆菌(Paenibacillus peoriae)CICC6240。
食品级植物乳杆菌CICC 6240,属于植物乳杆菌植物亚种,拉丁名称Lactobacillus plantarum subsp.Plantarum,为已知的生物材料。本发明所述植物乳杆菌CICC 6240保藏于北京市朝阳区酒仙桥中路24号院6号楼,中国工业微生物菌种保藏管理中心(China Center of Industrial Culture Collection,CICC)。此外,本发明所述植物乳杆菌CICC 6240同时还保藏于日本微生物菌种保藏中心,保藏编号JCM 1149;保藏于美国模式培养物集存库,保藏编号ATCC 14917;德国微生物菌种保藏中心,保藏编号DSM 20174;日本发酵研究所,保藏编号IFO 15981。本发明所述植物乳杆菌CICC 6240在本发明申请日前可以通过国内外商业渠道购买,如可向中国工业微生物菌种保藏管理中心购买菌株;向美国模式培养物集存库(American type culture collection,ATCC)等机构购买。
上述应用中,所述应用具体可为如下至少一种:
A1、在加速消减水产品体内抗生素中的应用;
A2、在提高抗生素胁迫下水产品抗氧化能力中的应用;
A3、在增强抗生素胁迫下水产品免疫力中的应用;
A4、在抑制抗生素胁迫下水产品炎症反应中的应用;
A5、在抑制抗生素胁迫下水产品细胞凋亡中的应用;
A6、在增强抗生素胁迫下水产品肌肉品质中的应用。
上述应用中,所述抗生素可为氯霉素和/或恩诺沙星。
上述应用中,所述水产品可为鱼。
为了解决以上技术问题,本发明还提供了植物乳杆菌在制备消减水产品中抗生素残留的产品中的应用。
上述应用中,所述植物乳杆菌为植物乳杆菌(Paenibacillus peoriae)CICC6240。
上述应用中,所述应用具体可为如下至少一种:
B1、在制备加速消减水产品体内抗生素的产品中的应用;
B2、在制备提高抗生素胁迫下水产品抗氧化能力的产品中的应用;
B3、在制备增强抗生素胁迫下水产品免疫力的产品中的应用;
B4、在制备抑制抗生素胁迫下水产品炎症反应的产品中的应用;
B5、在制备抑制抗生素胁迫下水产品细胞凋亡的产品中的应用;
B6、在制备增强抗生素胁迫下水产品肌肉品质的产品中的应用。
上述应用中,所述抗生素可为氯霉素和/或恩诺沙星。
上述应用中,所述水产品可为鱼。
上述应用中,所述产品的活性成分可为植物乳杆菌CICC 6240或/和植物乳杆菌CICC 6240的代谢物或/和植物乳杆菌CICC 6240的培养物,上述产品的活性成分还可含有其他生物成分或非生物成分,上述产品的其他活性成分本领域技术人员可根据产品的效果确定。
上述应用中,所述产品可为液体菌剂或固体菌剂。
上述应用中,所述产品还可包括载体。所述载体可为固体载体或液体载体。所述固体载体为矿物材料、生物材料;所述矿物材料可为草炭、粘土、滑石、高岭土、蒙脱石、白碳、沸石、硅石和硅藻土中的至少一种;所述生物材料为各类作物的秸秆、松壳、稻草、花生壳、玉米粉、豆粉、淀粉、草炭和动物的粪便中的至少一种;所述液体载体可为水;所述产品中,植物乳杆菌CICC 6240或/和植物乳杆菌CICC 6240的代谢物可以以被培养的活细胞、活细胞的发酵液、细胞培养物的滤液或细胞与滤液的混合物的形式存在。
上述应用中,所述产品的剂型可为多种剂型,如液剂、乳剂、悬浮剂、粉剂、颗粒剂、可湿性粉剂或水分散粒剂。
上述应用中,根据需要,所述产品中还可添加表面活性剂(如吐温20、吐温80 等)、粘合剂、稳定剂(如抗氧化剂)、pH调节剂等。
实验证明,本发明的植物乳杆菌CICC 6240具有加速鱼体氯霉素与恩诺沙星在鱼体消减;提高鱼体抗氧化能力、改善鱼体非特异性免疫、抑制炎症反应以及抑制组织细胞凋亡;并且提高鱼体肌肉品质的作用。此外,植物乳杆菌CICC 6240作为商品菌,广泛适用于水生动物,有望成为水生动物减抗退抗的新途径,从而推广应用与开发。
附图说明
图1为实施例1中氯霉素/恩诺沙星在抗生素富集鲤肝脏或肌肉中的药残含量。图1的A图为针对氯霉素(CAP)富集的鱼体模型试验后肝脏内氯霉素药残,图1的B图为针对氯霉素(CAP)富集的鱼体模型试验后肌肉内氯霉素药残,图1的C图为针对恩诺沙星(EFX)富集的鱼体模型试验后肝脏内恩诺沙星药残,图1的D图为针对恩诺沙星(EFX)富集的鱼体模型试验后肌肉内恩诺沙星药残。图中所示数据为平均值±标准差,重复数为3,以t检验分析各组显著性差异,*代表显著性分析结果为P<0.05,**代表显著性分析结果为P<0.01。
图2为实施例1中抗生素富集鲤肝脏抗氧化指标。图2的A图为总抗氧化能力测定结果,图2的B图为超氧化物歧化酶含量测定结果,图2的C图为过氧化氢酶含量测定结果,图4的D图为谷胱甘肽还原酶含量测定结果,图2的E图为丙二醛含量测定结果。图中CAP为针对氯霉素(CAP)富集的鱼体模型的试验结果,EFX为针对恩诺沙星(EFX)富集的鱼体模型的试验结果,所示数据为平均值±标准差,重复数为3,以t检验分析各组显著性差异,*代表显著性分析结果为P<0.05,**代表显著性分析结果为P<0.01,***代表显著性分析结果为P<0.001,****代表显著性分析结果为P<0.0001。
图3为实施例1中抗生素富集鲤肝脏免疫酶活力。图3的A图为溶菌酶活性测定结果,图3的B图为补体3含量测定结果,图3的C图为补体4含量测定结果,图3的D图为碱性磷酸酶活性测定结果,图3的E图为酸性磷酸酶活性测定结果,图3的F图为免疫球蛋白M含量测定结果。图中CAP为针对氯霉素(CAP)富集的鱼体模型的试验结果,EFX为针对恩诺沙星(EFX)富集的鱼体模型的试验结果,所示数据为平均值±标准差,重复数为3,以t检验分析各组显著性差异,*代表显著性分析结果为P<0.05,**代表显著性分析结果为P<0.01,***代表显著性分析结果为P<0.001。
图4为实施例1中抗生素富集鲤肝脏炎症因子含量。图4的A图为肿瘤坏死因子-α含量测定结果,图4的B图为白介素-1β含量测定结果,图4的C图为干扰素-γ含量测定结果,图4的D图为转化生长因子-β含量测定结果。图中CAP为针对氯霉素(CAP)富集的鱼体模型的试验结果,EFX为针对恩诺沙星(EFX)富集的鱼体模型的试验结果,所示数据为平均值±标准差,重复数为3,以t检验分析各组显著性差异,*代表显著性分析结果为P<0.05,**代表显著性分析结果为P<0.01,***代表显著性分析结果为P<0.001。
图5为实施例5中抗生素富集鲤肝脏细胞凋亡因子含量。图5的A图为半胱氨酸蛋白酶-3含量测定结果,图5的B图为半胱氨酸蛋白酶-8含量测定结果,图5的C图为半胱氨酸蛋白酶-9含量测定结果。图中CAP为针对氯霉素(CAP)富集的鱼体模型的试验结果,EFX为针对恩诺沙星(EFX)富集的鱼体模型的试验结果,所示数据为平均值±标准差,重复数为3,以t检验分析各组显著性差异,*代表显著性分析结果为P<0.05,**代表显著性分析结果为P<0.01,***代表显著性分析结果为P<0.001。
图6为实施例1中抗生素富集鲤肌肉生长相关基因表达量。图6的A图为氯霉素(CAP)富集的鱼体模型中肌细胞生成素(Myogenin)的基因相对表达量,图6的B图为氯霉素(CAP)富集的鱼体模型中肌肉生长抑制素(Myostatin)的基因相对表达量,图6的C图为恩诺沙星(EFX)富集的鱼体模型中成肌细胞测定蛋白(Myod)的基因相对表达量,图6的D图为恩诺沙星(EFX)富集的鱼体模型中肌细胞生成素(Myogenin)的基因相对表达量。图中所示数据为平均值±标准差,重复数为3,以t检验分析各组显著性差异,*代表显著性分析结果为P<0.05,***代表显著性分析结果为P<0.001,****代表显著性分析结果为P<0.0001。
具体实施方式
下面结合具体实施方式对本发明进行进一步的详细描述,给出的实施例仅为了阐明本发明,而不是为了限制本发明的范围。以下提供的实施例可作为本技术领域普通技术人员进行进一步改进的指南,并不以任何方式构成对本发明的限制。
下述实施例中的实验方法,如无特殊说明,均为常规方法,按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。如无特殊说明,以下实施例中的定量试验,均设置三次重复实验,结果取平均值。
下述实施例中的植物乳杆菌CICC 6240为植物乳杆菌植物亚种,拉丁名称Lactobacillus plantarum subsp.Plantarum,为中国工业微生物菌种保藏管理中心(China Center of Industrial Culture Collection,CICC,地址是北京市朝阳区酒仙桥中路24号院6号楼)的菌株。此外,植物乳杆菌CICC 6240同时还保藏于日本微生物菌种保藏中心,保藏编号JCM 1149;保藏于美国模式培养物集存库,保藏编号ATCC 14917;德国微生物菌种保藏中心,保藏编号DSM 20174;日本发酵研究所,保藏编号IFO 15981。本发明所述植物乳杆菌CICC 6240在本发明申请日前可以通过国内外商业渠道购买,如可向中国工业微生物菌种保藏管理中心购买菌株,CICC设有专门网站,网站地址为:http://www.china-cicc.org,公众可以直接在网上进行菌种订购,其网址是http://www.china-cicc.org/search/?classtype=0&keyword=6240;也可向美国典型培养物保藏中心(American typeculture collection,ATCC)等机构购买,ATCC设有专门网站,网站地址为:https://www.atcc.org,其网址是https://www.atcc.org/products/14917。植物乳杆菌CICC 6240即为如下文献中的ATCC strain 14917:Mayo B,et al.Cloning and characterizationof cspL and cspP,two cold-inducible genes from Lactobacillusplantarum.J.Bacteriol.179:3039-3042,1997.实施例1、CICC 6240对抗生素富集的鲤鱼的影响
本实施通过先构建抗生素富集的鲤鱼模型,再利用植物乳杆菌CICC 6240对其进行抗生素药残消减。
首先,建立抗生素富集的鱼体模型:
1)、用富含氯霉素(Chloramphenicol,CAP)的饲料(>99%,2.0g/kg)(基础饲料配方见表1,在基础饲料的基础上添加氯霉素至氯霉素在饲料中的含量为2.0g/kg)连续投喂总体重为365g的鲤(Cyprinus carpio)5d,每天4次(7:00,12:00,17:00和21:00)饱食投喂,建立氯霉素(CAP)富集的鱼体模型。
2)、用富含恩诺沙星(Enrofloxacin,EFX)的饲料(>98%,1.5g/kg)(基础饲料配方见表1,在基础饲料的基础上添加恩诺沙星至恩诺沙星在饲料中的含量为1.5g/kg)连续投喂总体重为365g的鲤5d,每天4次(7:00,12:00,17:00和21:00)饱食投喂,建立恩诺沙星(EFX)富集的鱼体模型。
表1:基础饲料配方
原料(%) | (g/kg) | 营养成分 | 含量(%) |
米糠 | 100.00 | 粗蛋白 | 38.65 |
面粉 | 200.00 | 粗脂肪 | 11.64 |
豆粕 | 200.00 | 灰分 | 9.33 |
菜粕 | 130.00 | 水分 | 4.07 |
国产鱼粉 | 80.00 | ||
鸡肉粉 | 120.00 | ||
DDGS | 100.00 | ||
膨润土 | 5.00 | ||
赖氨酸 | 2.00 | ||
蛋氨酸 | 0.50 | ||
氯化胆碱 | 2.00 | ||
磷酸二氢钙 | 20.00 | ||
豆油 | 30.00 | ||
VC磷酸酯 | 0.50 | ||
预混料 | 10.00 |
再在上次两种抗生素富集的鱼体模型的基础上,向水体中补充植物乳杆菌CICC6240菌体,具体处理如下:
试验I、针对氯霉素(CAP)富集的鱼体模型的试验设置:
氯霉素(CAP)富集的鱼体模型试验组(记为“1×106”):每7天向水体中添加一次植物乳杆菌CICC 6240,每次添加剂量均使水体中植物乳杆菌CICC 6240的含量为1×106cfu/mL,总共添加3次。将第一次添加植物乳杆菌CICC 6240的当天记作第0天(植物乳杆菌CICC6240浸浴的第0天)。
氯霉素(CAP)富集的鱼体模型对照组(CK):不添加植物乳杆菌CICC 6240。
每组三个重复,每个重复15条鲤。
试验II、针对恩诺沙星(EFX)富集的鱼体模型的试验设置:
恩诺沙星(EFX)富集的鱼体模型试验组:添加CICC 6240菌体(1×106CFU/mL,每7d补充一次菌)。
恩诺沙星(EFX)富集的鱼体模型对照组(CK):不添加CICC 6240。
每组三个重复,每个重复15条鲤。
对试验I和试验II均做如下7种取样与测定:
1、CICC 6240对氯霉素/恩诺沙星在鲤肝脏和肌肉中的药残含量的影响
在植物乳杆菌CICC 6240浸浴后的第3d,7d,14d分别检测鲤肝脏与肌肉药残含量。
结果见图1,表明:CICC 6240消减鲤肝脏中氯霉素(CAP)和恩诺沙星(EFX)都是从第7d开始发挥功效,药残含量显著降低(图1的A图、图1的C图);而在肌肉中,CICC 6240浸浴3d后氯霉素(CAP)和恩诺沙星(EFX)药残含量显著升高,之后逐渐降低,第7d时氯霉素(CAP)药残含量极显著下降,而恩诺沙星(EFX)药残量在7d,14d均无显著差异(图1的B图、图1的D图)。
2、CICC 6240对抗生素胁迫下鲤肝脏抗氧化能力的影响
在植物乳杆菌CICC 6240浸浴后的第7d,14d取鲤肝脏,检测鲤总抗氧化能力(T-AOC)、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)、谷胱甘肽还原酶(GR)活性和丙二醛(MDA)含量。T-AOC采用ABTS速测法、SOD为黄嘌呤氧化酶法、CAT是可见光测定法、GR采用紫外分光光度法、MDA采用TBA法。总抗氧化能力、超氧化物歧化酶和丙二醛试剂盒购买于碧云天生物技术;过氧化氢酶与谷胱甘肽还原酶试剂盒购买于南京建成生物科技。
结果见图2,表明:CICC 6240浸浴抗生素氯霉素(CAP)建模鲤或恩诺沙星(EFX))建模鲤7-14d,鱼体的抗氧化酶活力均显著升高(图2的A图、图2的B图、图2的C图、图2的D图),脂质过氧化产物MDA显著下降(图2的E图),表明CICC 6240对抗生素攻击下的鲤鱼抗氧化系统有积极保护作用。
3、CICC 6240对抗生素胁迫下鲤肝脏免疫酶活力的影响
在植物乳杆菌CICC 6240浸浴后的第7d,14d取鲤肝脏,检测鲤溶菌酶(LZM)、碱性磷酸酶(AKP)、酸性磷酸酶(ACP)酶活性,以及补体3(C3)、补体4(C4)、免疫球蛋白M(IgM)含量。LZM采用比浊法、AKP和ACP采用对硝基苯磷酸盐法、C3,C4与IgM采用双抗体夹心ELISA检测。溶菌酶、碱性磷酸酶、酸性磷酸酶和免疫球蛋白M试剂盒购买于南京建成生物科技;补体3和补体4试剂盒购买于上海酶免有限公司。
结果见图3,表明:CICC 6240浸浴7d后,氯霉素(CAP)建模鱼体免疫酶活力下降,第14d时效果回升,鲤溶菌酶(LZM)活性在氯霉素(CAP)与恩诺沙星(EFX)建模鱼上显著升高(图3的A图),碱性磷酸酶(AKP)活性(图3的D图)与IgM含量(图3的F图)在氯霉素(CAP)建模鱼上显著升高,C4含量(图3的C图)在恩诺沙星(EFX)建模鱼上显著升高。
4、CICC 6240对抗生素胁迫下鲤肝脏炎症的影响
在植物乳杆菌CICC 6240浸浴后的第7d,14d取抗生素鲤肝脏,检测鲤肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)、干扰素-γ(IFN-γ)和转化生长因子-β(TGF-β)含量。检测方法为双抗体夹心ELISA法,肿瘤坏死因子-α、白介素-1β、干扰素-γ和转化生长因子-β试剂盒购买于上海酶免有限公司。
结果见图4,表明:CICC 6240浸浴抗生素氯霉素(CAP)建模鲤或恩诺沙星(EFX))建模鲤7-14d,鱼体促炎因子TNF-α、IL-1β含量显著下降(图4A-B),但抗炎因子TGF-β含量无明显变化(图3的D图),表明CICC 6240可缓解抗生素攻击下的鲤鱼炎症反应。
5、CICC 6240对抗生素胁迫下鲤肝脏内细胞凋亡因子水平的影响
在植物乳杆菌CICC 6240浸浴后的第7d,14d取抗生素富集的鲤肝脏,检测鲤半胱氨酸蛋白酶-3(Caspase3)、半胱氨酸蛋白酶-8(Caspase8)、半胱氨酸蛋白酶-9(Caspase9)含量。检测方法为双抗体夹心ELISA法,半胱氨酸蛋白酶-3,8,9试剂盒购买于上海酶免有限公司。
结果见表5,表明:CICC 6240浸浴抗生素氯霉素(CAP)建模鲤或恩诺沙星(EFX))建模鲤7-14d,鱼体凋亡因子含量显著下降(图5的A图、图5的B图、图5的C图),表明CICC 6240可有效抑制抗生素攻击下鲤鱼的细胞凋亡。
6、CICC 6240对抗生素鲤肌肉生长相关基因表达量的影响
在植物乳杆菌CICC 6240浸浴后的第7d,14d后取鲤肌肉,检测鲤肌肉品质相关基因成肌细胞测定蛋白(Myod)、肌细胞生成素(Myogenin)、肌肉生长抑制素(Myostatin)的基因表达量。使用TRIzol法提取抗生素鲤肌肉的RNA。每个处理3个重复。将样品置于无RNase的离心管中,加入250μL Trizol,充分震荡破碎样品后补足Trizol至1mL,并置于室温3min使细胞充分裂解。加入200μL三氯甲烷,振荡15s,室温静置3min后12000g离心15min。小心吸取300μL上清到新的离心管中,加入200μL无水乙醇,轻轻混匀,转入RNase-free吸附柱CR3,12000g离心1min。600μL漂洗液RW洗涤2次,12000g空离柱子2min。加入50μL DEPC H2O溶解总RNA。测定RNA浓度后,按照1μg的量进行基因组DNA去除及反转录。获得cDNA后稀释5倍进行荧光定量PCR,检测肌肉生长调节基因的表达情况,内参为β-actin。引物如下:
针对Myod基因的引物为:
Myod-F:5’-CGATGCCTCCAGTCCGAGAT-3’;
Myod-R:5’-GCTGTCATAACTGTTCCGTCTTCTA-3’。
针对Myogenin基因的引物为:
Myogenin-F:5’-GGCTCCTCAAGGGATGTCG-3’;
Myogenin-R:5’-TCAGACGCACTGCTCCACTCT-3’。
针对Myostatin基因的引物为:
Myostatin-F:5’-GAGCCTGACCCCATCGTTC-3’;
Myostatin-R:5’-ATCGTATTCGTATGTGCCTTCCT-3’。
针对内参β-actin的引物为:
β-actin-F:5’-ATCCGTAAAGACCTGTATGCCA-3’;
β-actin-R:5’-GGGGAGCAATGATCTTGATCTTCA-3’。
结果显示,肌细胞生成素(Myogenin)、肌肉生长抑制素(Myostatin)以及成肌细胞测定蛋白(Myod)、在CICC 6240浸浴后显著上调(图6的A图、图6的B图、图6的C图、图6的D图),表明CICC 6240有提高肌肉生长调节基因的功能,可改善抗生素胁迫下鱼肉品质。
以上对本发明进行了详述。对于本领域技术人员来说,在不脱离本发明的宗旨和范围,以及无需进行不必要的实验情况下,可在等同参数、浓度和条件下,在较宽范围内实施本发明。虽然本发明给出了特殊的实施例,应该理解为,可以对本发明作进一步的改进。总之,按本发明的原理,本申请欲包括任何变更、用途或对本发明的改进,包括脱离了本申请中已公开范围,而用本领域已知的常规技术进行的改变。按以下附带的权利要求的范围,可以进行一些基本特征的应用。
Claims (5)
1.植物乳杆菌在制备提高抗生素胁迫下鲤鱼肝脏抗氧化能力的产品中的应用,其特征在于:所述植物乳杆菌为植物乳杆菌亚种(Lactobacillus plantarum subsp.Plantarum),其在中国工业微生物菌种保藏管理中心的登记入册编号为CICC 6240;
所述抗生素为氯霉素和/或恩诺沙星。
2.植物乳杆菌在制备增强抗生素胁迫下鲤鱼免疫力的产品中的应用,其特征在于:所述植物乳杆菌为植物乳杆菌亚种(Lactobacillus plantarum subsp.Plantarum),其在中国工业微生物菌种保藏管理中心的登记入册编号为CICC 6240;
所述抗生素为氯霉素和/或恩诺沙星。
3.植物乳杆菌在制备抑制抗生素胁迫下鲤鱼肝脏炎症反应的产品中的应用,其特征在于:所述植物乳杆菌为植物乳杆菌亚种(Lactobacillus plantarum subsp.Plantarum),其在中国工业微生物菌种保藏管理中心的登记入册编号为CICC 6240;
所述抗生素为氯霉素和/或恩诺沙星。
4.植物乳杆菌在制备抑制抗生素胁迫下鲤鱼肝脏细胞凋亡的产品中的应用,其特征在于:所述植物乳杆菌为植物乳杆菌亚种(Lactobacillus plantarum subsp.Plantarum),其在中国工业微生物菌种保藏管理中心的登记入册编号为CICC 6240;
所述抗生素为氯霉素和/或恩诺沙星。
5.植物乳杆菌在制备增强抗生素胁迫下鲤鱼肌肉生长调节基因表达的产品中的应用,其特征在于:所述植物乳杆菌为植物乳杆菌亚种(Lactobacillus plantarumsubsp.Plantarum),其在中国工业微生物菌种保藏管理中心的登记入册编号为CICC 6240;
所述抗生素为氯霉素和/或恩诺沙星。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211026125.2A CN115381005B (zh) | 2022-08-25 | 2022-08-25 | 植物乳杆菌cicc 6240在消减水产品体内抗生素残留中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211026125.2A CN115381005B (zh) | 2022-08-25 | 2022-08-25 | 植物乳杆菌cicc 6240在消减水产品体内抗生素残留中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115381005A CN115381005A (zh) | 2022-11-25 |
CN115381005B true CN115381005B (zh) | 2023-09-19 |
Family
ID=84122931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211026125.2A Active CN115381005B (zh) | 2022-08-25 | 2022-08-25 | 植物乳杆菌cicc 6240在消减水产品体内抗生素残留中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115381005B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116998593B (zh) * | 2023-09-15 | 2024-06-28 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 植物乳杆菌在提高鱼糖耐受能力制剂中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009138092A1 (en) * | 2008-05-13 | 2009-11-19 | OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it |
CN105831465A (zh) * | 2016-03-25 | 2016-08-10 | 青岛农业大学 | 一株植物乳杆菌在降低大规模肉鸡养殖时抗生素残留中的应用 |
CN106434430A (zh) * | 2016-09-07 | 2017-02-22 | 中山市润泽生物科技有限公司 | 一种降解抗生素与农药残留的复合微生物菌剂及其制备与应用 |
KR20170082484A (ko) * | 2017-07-03 | 2017-07-14 | 주식회사 이뮤너스 | 락토바실러스 플란타룸 fgl0001 및 이를 이용한 어류의 면역 증진 방법 |
CN109266587A (zh) * | 2018-11-09 | 2019-01-25 | 内蒙古农业大学 | 一种具有农药降解活性的植物乳杆菌、其制备方法及应用 |
-
2022
- 2022-08-25 CN CN202211026125.2A patent/CN115381005B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009138092A1 (en) * | 2008-05-13 | 2009-11-19 | OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it |
CN105831465A (zh) * | 2016-03-25 | 2016-08-10 | 青岛农业大学 | 一株植物乳杆菌在降低大规模肉鸡养殖时抗生素残留中的应用 |
CN106434430A (zh) * | 2016-09-07 | 2017-02-22 | 中山市润泽生物科技有限公司 | 一种降解抗生素与农药残留的复合微生物菌剂及其制备与应用 |
KR20170082484A (ko) * | 2017-07-03 | 2017-07-14 | 주식회사 이뮤너스 | 락토바실러스 플란타룸 fgl0001 및 이를 이용한 어류의 면역 증진 방법 |
CN109266587A (zh) * | 2018-11-09 | 2019-01-25 | 内蒙古农业大学 | 一种具有农药降解活性的植物乳杆菌、其制备方法及应用 |
Non-Patent Citations (1)
Title |
---|
饲用枯草芽孢杆菌HGcc-1对鲤肠肝健康、血清补体及肠道菌群的影响;胡娟等;水产学报;第1753−1763页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115381005A (zh) | 2022-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Influences of quorum‐quenching probiotic bacteria on the gut microbial community and immune function in weaning pigs | |
Zoghi et al. | Surface binding of toxins and heavy metals by probiotics | |
Castillo et al. | Use of mannanoligosaccharides and zinc chelate as growth promoters and diarrhea preventative in weaning pigs: effects on microbiota and gut function | |
JP5666906B2 (ja) | フィターゼを高レベルで分泌する胆汁耐性バチルス組成物 | |
Armando et al. | Saccharomyces cerevisiae strains from animal environment with in vitro aflatoxin B1 binding ability and anti-pathogenic bacterial influence | |
Harnentis et al. | Novel probiotic lactic acid bacteria isolated from indigenous fermented foods from West Sumatera, Indonesia | |
El-Baz et al. | Semi-industrial scale production of a new yeast with probiotic traits, Cryptococcus sp. YMHS, isolated from the Red Sea | |
NO330198B1 (no) | Anvendelse av melkesyrebakteriestamme og naeringssammensetning for kjaeledyr. | |
CN115381005B (zh) | 植物乳杆菌cicc 6240在消减水产品体内抗生素残留中的应用 | |
Zhao et al. | Protective effect of Devosia sp. ANSB714 on growth performance, serum chemistry, immunity function and residues in kidneys of mice exposed to deoxynivalenol | |
Poloni et al. | Bakery by-products based feeds borne-Saccharomyces cerevisiae strains with probiotic and antimycotoxin effects plus antibiotic resistance properties for use in animal production | |
Magnoli et al. | Novel yeast isolated from broilers’ feedstuff, gut and faeces as aflatoxin B1 adsorbents | |
Damayanti et al. | Characterization of lactic acid bacteria as poultry probiotic candidates with aflatoxin B1 binding activities | |
Vamanu et al. | Antioxidative effects of phenolic compounds of mushroom mycelia in simulated regions of the human colon, in vitro study | |
Sun et al. | Aflatoxin B1 decontamination by UV-mutated live and immobilized Aspergillus niger | |
Ibitoye et al. | Lactic acid bacteria bio-detoxified aflatoxins contaminated cereals, ameliorate toxicological effects and improve haemato-histological parameters in albino rats | |
JP6785324B2 (ja) | α−グルコシダーゼ阻害剤を多量生産するバチルス・リケニフォルミスNY1505菌株 | |
KR100557397B1 (ko) | 유해미생물 억제 활성을 가지는 신규 내산성 락토바실러스 루테리 Probio-054 및 이를 함유하는 생균활성제 | |
Marimuthu et al. | Effect of biofloc technology enriches the growth of Litopenaeus vannamei (Boone, 1931) | |
CN117187113A (zh) | 一株副干酪乳杆菌dt11及其在制备微塑料吸附、清除及促进排便功能的产品中的应用 | |
Hossain et al. | Edible growth medium: a new window for probiotic research | |
Vanaki et al. | Isolation and identification of keratinolytic probiotic Bucillus licheniformis bacteria from the soil below poultry slaughterhouse waste | |
Lata et al. | PROBIOTIC CHARACTERIZATION OF SACCHAROMYCES CEREVISIAE Y196 AND Y197 ISOLATED FROM RICE CHHANG-A FERMENTED BEVERAGE OF LAHAUL SPITI | |
KR20210063994A (ko) | 신규한 락토바실러스 파라카제이 nsmj15 균주 및 이를 함유하는 동물용 사료첨가제 | |
KR20030063961A (ko) | 돼지 전염성위장염 (TGE) 코로나바이러스 및 유해 미생물억제 활성을 갖는 신규 락토바실러스 프란타럼 Probio-38및 이를 함유하는 생균활성제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |